再鼎医药(ZLAB.US)涨逾7% 注射用ZL-1310拟纳入突破性疗法

Core Viewpoint - Zai Ding Pharmaceutical (ZLAB.US) saw a more than 7% increase in stock price, reaching $20.11, following the announcement that its injectable ZL-1310 is proposed to be included as a breakthrough therapy for extensive-stage small cell lung cancer (ES-SCLC) patients during or after platinum-based treatment [1] Group 1 - ZL-1310 has shown outstanding efficacy data in early clinical studies, particularly in patients receiving second-line treatment and those with brain metastases, indicating its potential to become a breakthrough therapy in the SCLC treatment field [1]